Literature DB >> 15733399

[Bilateral primary breast cancer: a report of 217 cases].

Tao Zhang1, Bao-ning Zhang.   

Abstract

OBJECTIVE: To report the clinical and pathological characteristics of bilateral primary breast cancer (BPBC) in comparison with unilateral primary breast cancer (UPBC).
METHODS: A retrospect database of primary breast cancer patients admitted to the Cancer Hospital from March 1967 through May 2003 was analyzed.
RESULTS: A total of 10,470 primary breast cancer patients were treated, among which 271 patients had bilateral primary tumors with an incidence of 2.1%. Most of the BPBC, developed both synchronously (sBPBC, incidence rate: 0.6%) and metachronously (mBPBC, incidence rate: 1.5%), were diagnosed in premenopausal women with an average age of 48. In the latter cases, the median time interval between their occurrences was 57.6 months. The median survival time for patients with sBPBC and mBPBC was 29.6 months and 27.8 months, respectively. There was no statistical difference in survival rate between the 2 groups of patients. Nor was menopausal status related to survival. In mBPBC patients, when the occurrence of the second breast cancer was taken as the beginning of prognostic analysis, the prognosis of BPBC patients was worse than those with unilateral involvement.
CONCLUSION: Prognosis of patients with bilateral primary breast cancer is poor. In mBPBC patients whose breast cancers appear one after the other, meticulous follow-up is needed after resection of tumor on one side to early detect development of cancer of the countralateral breast especially within 5 years.

Entities:  

Mesh:

Year:  2004        PMID: 15733399

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  1 in total

1.  HER2 positive bilateral metachronous primary breast carcinoma: A case report.

Authors:  Jinghao Yao; Jing Liu; Yawei Li; Yumei Li; Qiong Wu; Yan Yang
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.